Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bmab-1700 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Phase 1 | United States | 01 Aug 2026 | |
| Melanoma | Phase 1 | Brazil | 01 Aug 2026 | |
| Melanoma | Phase 1 | Chile | 01 Aug 2026 | |
| Melanoma | Phase 1 | Moldova | 01 Aug 2026 | |
| Melanoma | Phase 1 | Romania | 01 Aug 2026 | |
| Melanoma | Phase 1 | Serbia | 01 Aug 2026 | |
| Melanoma | Phase 1 | South Africa | 01 Aug 2026 | |
| Melanoma | Phase 1 | Spain | 01 Aug 2026 | |
| Melanoma | Phase 1 | Turkey | 01 Aug 2026 | |
| Melanoma | Phase 1 | Ukraine | 01 Aug 2026 |






